{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P01579",
      "entity_text" : "IFNgamma",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01789",
      "entity_text" : "nivolumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "While no significant secondary cytokine increase was observed, nivolumab appeared to prolong the period of elevated cytokine production, notably IFNgamma and granzyme B, resulting in higher AUC 0-28 compared with ZUMA-1 (16,315 vs 2245 pg/mL x days [Q1-Q3, 1211-4883] and 2433 vs 153 pg/mL x days [66-320], respectively).",
  "reading_complete" : "2020-08-05T21:43:11Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T21:41:26Z",
  "trigger" : "prolong",
  "evidence" : [ "nivolumab appeared to prolong the period of elevated cytokine production, notably IFNgamma" ],
  "pmc_id" : "7269903",
  "score" : 0
}